Latest news with #Mesoblast
Yahoo
2 days ago
- Business
- Yahoo
Canaccord Genuity Initiates Coverage of Mesoblast Limited (MESO) with Buy Rating
Mesoblast Limited (NASDAQ:MESO) is among the 12 Best Australian Stocks to Buy Right Now. On August 5, Canaccord Genuity initiated coverage of the stock with a Buy rating and announced a price target of AUD 2.97 ($1.94) per share, with analyst Elyse Shapiro citing the company's promising cell therapy platform. A close up of the hand of a financial analyst, holding a copy of a report from a rating agency. The firm acknowledged Mesoblast Limited (NASDAQ:MESO)'s expertise in allogeneic therapies for severe inflammatory diseases, which use cells from a single donor, instead of requiring cells from the recipient or matched donors. Canaccord also highlighted the company's progenitor cell and mesenchymal stromal cell approach that reduces harmful inflammation by modulating the immune system. In other recent news, on July 17, Mesoblast Limited (NASDAQ:MESO) announced USD 13.2 million in gross revenue from Ryoncil sales post-launch. The drug is the first and only mesenchymal stromal cell product in the U.S. that is approved by the FDA. It became commercially available on March 28, 2025, for the treatment of steroid-refractory acute graft-versus-host disease in children. Mesoblast Limited (NASDAQ:MESO) is an Australian company focused on developing allogeneic cellular medicines to treat severe and life-threatening inflammatory conditions. While we acknowledge the potential of MESO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
Sky News AU
21-07-2025
- Business
- Sky News AU
ASX 200 sheds more than $25 billion on Monday after surging about 2.3 per cent over late last week
The ASX 200 has sank on Monday, clawing back a massive surge late last week that pushed the index to new record highs. The index fell 0.8 per cent in the first 50 minutes of trading, wiping more than $25 billion off local investors' portfolios. It follows the index rising 0.9 per cent on Thursday and another 1.4 per cent on Friday Australian regenerative medicine company Mesoblast shed 7.9 per cent after surging more than 32 per cent on Friday when it revealed strong results from the commercial launch of children's drug Ryoncil. Regis Resources has shed four per cent, while Insignia Financial is down 5.3 per cent and Lifestyle Communities has sank 2.5 per cent. Buy-now-pay-later company Block, which is led by Twitter-founder Jack Dorsey and listed on the Nasdaq, jumped about 10.9 per cent after news emerged it would join the S&P 500. Other strong performers include AMP, which jumped 5.5 per cent after revealing a strong second-quarter performance, and Clarity Pharmaceuticals which is up 4.9 per cent. Investors await the RBA meeting minutes due on Tuesday which will reveal the thinking behind the central bank's shock rate hold. Josh Gilbert, a market analyst with trading platform eToro, said further explanation of the decision, which three of the nine RBA board members disagreed with, will be critical for a better understanding of Australia's economy. 'We know RBA chair Michele Bullock leans towards quarterly (inflation) readings, not the monthly ones, for a more stable indicator of economic health and that this caution likely motivated her to vote for a pause, but analysts will be keen to get a deeper understanding of the board's broader perspective,' Mr Gilbert said. It was a mixed bag on Wall Street on Friday with both the S&P 500 and the Nasdaq finishing flat while the Dow Jones sank 0.3 per cent. London's FTSE 250 Index jumped 0.6 per cent, Germany's DAX shed 0.3 per cent and the STOXX Europe 600 finished flat. New Zealand's NZX 50 Index is up 0.4 per cent since trading began on Monday while Japan's Nikkei 225 is down 0.2 per cent.
News.com.au
18-07-2025
- Business
- News.com.au
Closing Bell: Party on the ASX as market amps up the bass, raves to new heights
ASX surges 1.37pc, smashing through record to close at 8757 points All 11 sectors neon green, up between 2.47pc and 0.46pc Healthcare and resources stocks crank higher, leading gains DJ play it louder It was a raver of a party on the ASX today, surging 1.37% in its best performance since April. Just as we'd finished celebrating its latest record breaking close last night, the ASX smashed through that barrier by a solid 100 points, setting the new ceiling at 8757. Traders were riffing off weaker-than-expected employment data at home yesterday – strongly signalling another interest rate cut in August – and better-than-expected retail data out of the US today. Retail numbers over the pond lifted 0.6% compared to fears of just 0.1% in June, soothing fears of a major economic slowdown and lowering simmering tensions between the White House and the Fed Reserve. It all came together to set a pulsing beat for Aussie trade today, with every sector joining the party again. Healthcare (+2.47%) and materials (+2.06%) were strutting their stuff, showing the rest of the market how it's done. The ASX 200 Resources index topped the indices charts today, lifting 1.88%, but the banks, tech and gold indices were enjoying the neon lights just as much. Health and resource stocks break it down With the entire market feeling the rhythm, let's take a closer look at why some stocks killed it in trade today. Mesoblast (ASX:MSB) pumped it up, surging 34.6% on sale numbers for its stem cell product Ryoncil. It's only been on the shelves since late March, but MSB has already raked in US$13.2 million gross revenue (unaudited). Clarity Pharmaceuticals (ASX:CU6) is also kicking it, hot stepping 11.7% higher after completing recruitment for a study assessing a new imaging agent for prostate cancer. It's a disease with a huge unmet need, and a global market estimated at US$12.9 billion. Flipping to our resources track, battery metals got a kick from surging lithium and rare earth stocks on Wall Street overnight, benefiting from improving sentiment around the critical commodities (and some fresh tension with China over supply chains). While they've had no news the last couple days, Pilbara Minerals (ASX:PLS) jumped 8.5% and Brazilian Rare Earths (ASX:BRE) 10.2%. They were joined by Iluka Resources (ASX:ILU), up just about 5% and Min Res (ASX:MIN) up 4.8%. We can't mention resources without acknowledging today's dancing queen – BHP (ASX:BHP) smashed it in trade, adding more than a dollar to its share price after hitting some of its best production numbers ever. ' iron ore out of WA smashed records, with South Flank running above nameplate in its first full year. Even the coal division chipped in, lifting output 5% despite getting slapped by wet weather and moody geology at Broadmeadow,' our own Eddy Sunarto reported in today's Lunch Wrap. 'Over in copper, BHP pumped out over 2 million tonnes group-wide, a record haul in a metal that's fast becoming the lifeblood of the clean energy boom.' BHP shares closed out the day 3% higher at $40.29 each. ASX SMALL CAP LEADERS Today's best performing small cap stocks: Code Name Last % Change Volume Market Cap IS3 I Synergy Group Ltd 0.002 100% 29425880 $1,706,300 TR2 Tali Resources Ltd 0.37 85% 2480529 $7,501,000 AS2 Askarimetalslimited 0.012 50% 43553469 $3,233,365 AUH Austchina Holdings 0.0015 50% 558600 $3,025,384 GGE Grand Gulf Energy 0.003 50% 11211 $5,640,850 VRC Volt Resources Ltd 0.005 43% 3745598 $16,396,973 DTZ Dotz Nano Ltd 0.041 37% 2134834 $17,761,929 VBS Vectus Biosystems 0.05 35% 65744 $1,971,298 ALR Altairminerals 0.004 33% 593100 $12,890,233 FAU First Au Ltd 0.004 33% 1234769 $6,228,874 HLX Helix Resources 0.002 33% 1760084 $5,046,291 SHP South Harz Potash 0.004 33% 1181196 $3,849,186 FAL Falconmetalsltd 0.665 32% 3759496 $89,385,000 BRX Belararoxlimited 0.08 31% 674443 $9,881,938 IPB IPB Petroleum Ltd 0.007 27% 1580453 $3,885,217 PIL Peppermint Inv Ltd 0.0025 25% 404020 $4,602,180 PXX Polarx Limited 0.01 25% 5175889 $19,004,008 ROG Red Sky Energy. 0.005 25% 527666 $21,688,909 CYP Cynata Therapeutics 0.185 23% 1513058 $33,893,155 CHL Camplifyholdings 0.49 23% 133350 $28,600,140 LMG Latrobe Magnesium 0.011 22% 16487031 $23,639,310 NVQ Noviqtech Limited 0.039 22% 721525 $8,049,170 ZGL Zicom Group Limited 0.14 22% 126775 $24,674,401 INF Infinity Lithium 0.017 21% 302402 $6,616,289 FRS Forrestaniaresources 0.145 21% 1666346 $37,322,691 Making news... With copper prices heating up, Askari Metals (ASX:AS2) is hitting all the right notes at the Nejo gold project in Ethiopia, unearthing 14m at 3.2% and 35m at 0.82% copper in historical drilling results. The company has at least 6 copper targets to hit with the drill bit, with one of particular interest stretching over a 600m by 30m strike. There's also more than 1170 square kilometres of project to explore in a fertile, underexplored region in the same greenstone belt as the 3.4-million-ounce Kurmuk Mine and the 1.7-million-ounce Tulu Kapi Mine. ASX SMALL CAP LAGGARDS Today's worst performing small cap stocks: Code Name Last % Change Volume Market Cap PAB Patrys Limited 0.001 -50% 4095800 $4,731,620 1TTDB Thrive Tribe Tech 0.011 -45% 688814 $2,031,723 AOK Australian Oil. 0.002 -33% 2400330 $3,005,349 CRB Carbine Resources 0.003 -25% 459 $4,000,652 CT1 Constellation Tech 0.0015 -25% 1956076 $2,949,467 EEL Enrg Elements Ltd 0.0015 -25% 20495001 $6,507,557 NPM Newpeak Metals 0.021 -25% 1155564 $9,018,008 BUY Bounty Oil & Gas NL 0.002 -20% 276214 $3,903,680 MEL Metgasco Ltd 0.002 -20% 120000 $4,581,467 QXR Qx Resources Limited 0.004 -20% 1157066 $6,551,644 TOU Tlou Energy Ltd 0.025 -19% 123162 $40,256,114 PLN Pioneer Lithium 0.115 -18% 17378 $6,182,636 ADG Adelong Gold Limited 0.005 -17% 16008493 $13,492,060 ADR Adherium Ltd 0.005 -17% 3640331 $9,438,997 CHM Chimeric Therapeutic 0.005 -17% 9498886 $12,091,165 TEG Triangle Energy Ltd 0.0025 -17% 1460016 $6,267,702 XPN Xpon Technologies 0.01 -17% 321808 $4,971,039 FRM Farm Pride Foods 0.29 -16% 244556 $79,622,983 ORD Ordell Minerals Ltd 0.35 -16% 427461 $17,773,483 SRI Sipa Resources Ltd 0.017 -15% 5553643 $8,327,966 AN1 Anagenics Limited 0.006 -14% 7576 $3,474,243 ECT Env Clean Tech Ltd. 0.003 -14% 200000 $14,054,024 ID8 Identitii Limited 0.006 -14% 29293 $5,446,095 OMG OMG Group Limited 0.006 -14% 201588 $5,098,064 TYX Tyranna Res Ltd 0.003 -14% 79120 $11,509,489 IN CASE YOU MISSED IT Aldoro Resources (ASX:ARN) continues to build the Kameelburg niobium and REE project's scale with TREO results up to 2.1pc. Break it Down: AnteoTech's (ASX:ADO) recent testing of its Ultranode X battery has achieved nearly 900 cycles at 80% capacity retention. Hillgrove Resources (ASX:HGO) made further operational improvements at Kanmantoo copper mine in South Australia, improving both mine development and ore processing numbers. TRADING HALTS
Business Insider
18-07-2025
- Business
- Business Insider
Mesoblast reports Q1 Ryoncil gross revenue $13.2M
Mesoblast (MESO) announced gross revenue from sales of Ryoncil through the first quarter post product launch. Ryoncil is the first and only FDA approved mesenchymal stromal cell product in the Unites States and became commercially available for purchase on March 28, 2025, within one quarter of receiving FDA approval for treatment of steroid-refractory acute graft-versus-host disease in children. Mesoblast Chief Executive Dr. Silviu Itescu said, 'We are pleased with the commercial launch activities of Ryoncil in the first quarter post-launch and look forward to updating on the current quarter's progress now that mandatory state CMS coverage has become effective as of July 1, and we complete onboarding of the remaining major U.S. transplant centers.' Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with , delivered to your inbox every week.
Yahoo
29-06-2025
- Business
- Yahoo
Mesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil
Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of orphan-drug exclusive approval from the US FDA for Ryoncil® (remestemcel-L) for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. This period of statutory exclusivity exhibits that the US FDA will not be approving any other mesenchymal stromal or stem cell (MSC) products for this indication during a 7-year period from the approval date of Ryoncil®. A biotechnologist in a lab suit studying a syringe with a mesenchymal lineage cells inside. Furthermore, Mesoblast Limited (NASDAQ:MESO) possesses biologic exclusivity preventing another sponsor from referencing the Ryoncil® biologic license application (BLA) till December 2036, 12 years from the 1st approval, preventing market entry by the biosimilar. Apart from such statutory exclusivities, Mesoblast Limited (NASDAQ:MESO) possesses a robust US intellectual property position on MSC composition of matter, manufacturing, and indications, including SR-aGvHD, which offers a commercial barrier to entry against the competitors through 2044. While we acknowledge the potential of MESO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MESO and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None.
